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Molecular cloning and expression of a unique receptor-like protein-tyrosine-
phosphatase in the leucocyte-common-antigen-related phosphatase family
Wei-Ren ZHANG, Naotake HASHIMOTO,* Faiyaz AHMAD, Wendi DING and Barry J. GOLDSTEINt
Dorrance H. Hamilton Research Laboratories, Division of Endocrinology and Metabolic Diseases, Department of Medicine, Jefferson Medical College,
Thomas Jefferson University, Philadelphia, PA 19107, U.S.A.
Protein-tyrosine-phosphatases (PTPases) have been implicated
in the regulation of certain tyrosine kinase growth factor
receptors in that they dephosphorylate the activated (auto-
phosphorylated) form of the receptors. In order to identify
PTPases that potentially act on receptor targets in liver, we used
the human leucocyte common antigen-related PTPase (LAR)
cDNA [Streuli, Krueger, Hall, Schlossman and Saito (1988) J.
Exp. Med. 168, 1523-1530] and isolated two closely related
transmembrane PTPase homologues from a rat hepatic cDNA
library. Both PTPases had large extracellular domains that
contained three immunoglobulin-like repeats and eight type-III
fibronectin repeats. Both enzymes had tandem homologous
PTPase domains following a single hydrophobic transmembrane
domain. One sequence encoded the rat homologue of LAR. The
second PTPase, designated LAR-PTP2, had 79 and 90 % identity
INTRODUCTION
Protein phosphorylation is an essential mechanism in the control
of cellular signalling through various physiological pathways.
Increasing attention is being paid to reversible phosphorylation
events involving protein tyrosine residues, which have been
implicated in such diverse aspects of cellular control as signalling
by insulin and other growth factors (Ullrich and Schlessinger,
1990; Myers and White, 1993), cell-cycle regulation (Gould et
al., 1990) and the recognition of antigens by T-cells (Pingel and
Thomas, 1989). Regulation of signalling through these pathways
has been shown also to involve one or more cellular protein
phosphatase enzymes with a marked or absolute specificity for
protein tyrosine residues (PTPases; EC 3.1.3.48) (Fischer et al.,
1991; Brautigan, 1992). In the case of the insulin holoreceptor,
which retains its phosphorylation state and activation of its
receptor kinase even after insulin is removed from the ligand-
binding site, dephosphorylation of specific tyrosine residues is
required to deactivate the intrinsic kinase activity of the receptor
(Goldstein, 1993).
A number of full-length and partial PTPase sequences have
now been cloned by several laboratories (Saito and Streuli, 1991;
Fischer et al., 1991; Pot and Dixon, 1992). These enzymes
comprise overlapping families of structurally related proteins
with conserved cytoplasmic catalytic domains of approx. 260
amino acids that occur as single and tandemly related regions.
The cloned enzymes may be divided into two broad categories:
with rat LAR in the respective cytoplasmic PTPase domains,
with only 57 % sequence similarity in the extracellular domain.
The catalytic domains of LAR and LAR-PTP2 prepared by
bacterial expression were active in dephosphorylating a variety
of phosphotyrosyl substrates but did not hydrolyse phospho-
serine or phosphothreonine residues of labelled casein. Both
enzymes exhibited rapid turnover numbers of 4-7 s-5 for myelin
basic protein and 78-150 s-5 for derivatized lysozyme. LAR and
LAR-PTP2 displayed similar PTPase activity towards the simul-
taneous dephosphorylation of receptors of intact insulin and
epidermal growth factor from liver membranes. These data
indicate that there is a family of LAR-related PTPases that may
regulate the phosphorylation state of receptor tyrosine kinases in
liver and other tissues.
receptor-type, which have a general structure like a membrane
receptor with a glycosylated extracellular domain, a single
transmembrane segment and one or two conserved PTPase
domains; and non-receptor-type, which lack a transmembrane
segment and typically have a single PTPase domain and ad-
ditional protein segments with various functional properties.
Some ofthe non-receptor-type PTPases include PTPasel B (Guan
et al., 1990; Chernoffet al., 1990; Brown-Shimer et al., 1990) and
the T-cell PTPase (Cool et al., 1989), which have C-terminal
hydrophobic domains that confer an association with the en-
doplasmic reticulum, PTPH1 and MEG (Yang and Tonks, 1991;
Gu et al., 1991), which have N-terminal domains homologous to
cytoskeleton-associated proteins, PTP1C (Shen et al., 1991;
Plutzky et al., 1992; Yi et al., 1992) and SH-PTP2 (Freeman et
al., 1992; Ahmad et al., 1993), which have two N-terminal SH2
domains that may promote their interaction with certain
phosphotyrosine-containing substrates, PEP (Matthews et al.,
1992), which has a proline-, glutamic acid-, serine- and threonine-
rich ('PEST') domain at the C-terminus, and HePTPase (Zanke
et al., 1992), which apparently lacks additional functional
domains and appears to be a cytosolic PTPase expressed in
lymphoid tissues.
The leucocyte common antigen (LCA) or CD45 (Trowbridge
et al., 1991) was the first member of the family of receptor-type
transmembrane PTPases to be identified. As CD45 was restricted
in its expression to haematopoietic tissues, Streuli et al. (1988)
used a CD45 cDNA probe to isolate a structurally related
Abbreviations used: DTT, dithiothreitol; PTPase, protein-tyrosine-phosphatase; LAR, leucocyte common antigen-related PTPase; LCA, leucocyte
common antigen; MBP, myelin basic protein; N-CAM, neural cell adhesion molecule; RCML, reduced carboxamidomethylated maleylated lysozyme;
poly(A)+, polyadenylated.
* Present address: Second Department of Internal Medicine, Chiba University School of Medicine, Chiba, Japan.
t To whom correspondence should be addressed.
The sequences reported in this paper have been deposited in the EMBL/GenBank DDBJ Nucleotide Sequence Databases under the following
accession numbers: rat LAR, L11586; rat LAR-PTP2, L11587; rat LAR-PTP2B, L12329.
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PTPase homologue from a human placental library, called the
leucocyte common antigen-related phosphatase (LAR), which is
expressed in liver and a variety of cell lines and tissues (Streuli et
al., 1988; Goldstein et al., 1991). Additional receptor-type
PTPases have been cloned by several laboratories from mam-
malian tissue sources including LRP, for LCA-related
phosphatase (also termed RPTP-a) (Matthews et al., 1990; Sap
et al., 1990; Krueger et al., 1990), RPTP-,/, RPTP-8, RPTP-c
(Krueger et al., 1990), RPTP-,t (Gebbink et al., 1991) and
RPTP-C (Krueger and Saito, 1992). Krueger et al. (1990) have
also provided evidence that LAR and RPTP-8 have a close
phylogenetic relationship and may comprise a subfamily of
transmembrane PTPases.
Our laboratory is interested in isolating PTPases that are
expressed in liver and other insulin-sensitive tissues in order to
characterize their potential physiological role in the regulation of
receptor tyrosine kinase activity and growth factor action. As the
bulk of insulin-receptor dephosphorylating activity is localized
to a particulate fraction of liver and hepatoma cells, we used a
cDNA fragment from the human transmembrane PTPase, LAR,
as a probe for molecular cloning ofadditional related homologues
at reduced stringency in a rat liver cDNA library. A unique
transmembrane PTPase homologue in the LAR family was
isolated and characterized. The activity of the cytoplasmic
domains of the cloned PTPases was also evaluated using a
bacterial expression system and several tyrosine-phosphorylated
protein substrates including intact receptors for insulin and
epidermal growth factor.
EXPERIMENTAL
Materials
A mixed oligo(dT) and random hexamer-primed cDNA library
in AZAPII prepared from the liver of a male Sprague-Dawley rat
was obtained from Stratagene (La Jolla, CA, U.S.A.). DNA
restriction endonucleases and modifying enzymes were purchased
from New England Biolabs (Beverly, MA, U.S.A.) or Promega
(Madison, WI, U.S.A.). Oligonucleotides were purchased from
Oligos Etc. (Wilsonville, OR, U.S.A.). Thermus aquaticus DNA
polymerase was purchased from Perkin-Elmer Cetus (Norwalk,
CT, U.S.A.). Modified T7 DNA polymerase for sequencing was
obtained from U.S. Biochemical (Cleveland, OH, U.S.A.). [a-
[35S]thio]dATP and [y-32P]ATP were from New England Nuclear
(Beverly, MA, U.S.A.). The pGEX-KG expression vector was
purchased from the American Type Culture Collection. Myelin
basic protein (MBP) and reduced carboxamidomethylated mal-
eylated lysozyme (RCML) were from Sigma (St. Louis, MO,
U.S.A.).
cDNA cloning
One million phage plaques of the rat liver cDNA library were
hybridized (Sambrook et al., 1989) at reduced stringency in a
solution containing 40% (v/v) formamide, 0.1 % (w/v) Ficoll,
0.1% (w/v) poly(vinylpyrrolidone), 0.1% (w/v) BSA, 5 mM
EDTA, 0.1% (w/v) SDS, 100 ,ug/ml denatured salmon sperm
DNA, 750 mM NaCl and 50 mM NaH2PO4, pH 7.4, at 35 °C
with a labelled cDNA (Feinberg and Vogelstein, 1983) encoding
all but the extremes 5' end of the human LAR sequence (kindly
provided by Dr. Haruo Saito, Dana Farber Cancer Institute,
Boston, MA, U.S.A.). Filters were washed at 50 °C in buffer
containing 75 mM NaCl and 0.1% (w/v) SDS in 7.5 mM
trisodium citrate, pH 7.0. Twenty-four positive clones were
obtained and plaque-purified by secondary screening with the
same LAR cDNA probes. Insert-bearing pBluescript phagemids
were excised from the AZAPII clones using the helper phage
R408 and plasmids were prepared by infection of XL-1 Blue
Escherichia coil host cells (Stratagene Cloning Systems, 1988). In
a tertiary screening involving hybridization of plasmid DNA,
slot-blots were used to identify 15 clones that hybridized strongly
with the LAR domain probe (HindIII/EcoRI segment). Double-
stranded sequencing was then performed on both strands of the
cDNA clones using the chain-termination method of Sanger et
al. (1977) with T3 and T7 promoter primers, or synthetic 17-mer
oligonucleotides derived from previously obtained sequences,
and modified T7 DNA polymerase (U.S. Biochemical). For large
(> 2 kb) inserts, nested deletions were prepared for sequencing
each strand as described previously (Goldstein and Dudley,
1990).
Additional cDNA segments were obtained by cDNA walking
at high stringency in a rat brain cDNA library in AGT1O
(Stratagene). The remaining segments of the PTPase cDNAs
were cloned by an anchored reverse transcription PCR technique
(Frohman et al., 1988) employing poly(dA) tailing with terminal
transferase and amplification with Vent thermostable polymerase
(New England Biolabs).
Analysis of sequence homology
Sequences were tested for homology with the translated version
of the GenBank database, and amino acid alignments were
performed using programs in the EuGene package, both accessed
through the Molecular Biology Computer Research Resource at
Boston University.
Blot hybridization analyses
Male Sprague-Dawley rats weighing 150-175 g were obtained
from Taconic Farms (Germantown, NY, U.S.A.) and had free
access to food and water before being killed. RNA was prepared
from various rat tissues by the single-step method (Chomczynski
and Sacchi, 1987), and Northern-blot analysis was performed
with poly(A)+ RNA as described previously (Goldstein et al.,
1987). A blot containing 2 ,ug of poly(A)+ RNA from multiple rat
tissues was also hybridized according to directions supplied by
the manufacturer (Clontech). Genomic DNA was isolated from
rat liver (Ludwig et al., 1988) and after digestion with the
indicated restriction enzyme, 5,ug was subjected to electro-
phoresis in a 0.8% agarose gel in buffer consisting of 50 mM
boric acid, 1 mM EDTA and 50 mM Tris/HCl, pH 7.0, de-
natured, and transferred to nitrocellulose. Filters were hybridized
with cDNA fragments labelled by random hexamer priming
(Feinberg and Vogelstein, 1983).
Purification of bacterially expressed PTPase catalytic domains
For enzyme studies, the entire cytoplasmic domains ofLAR and
LAR-PTP2 were expressed as glutathione S-transferase fusion
proteins in the pGEX-KG vector system using standard methods
similar to those described by Hashimoto et al. (1992b). The final
subcloned products for LAR and LAR-PTP2 expression were
checked by restriction mapping and sequencing of plasmid
inserts.
Recombinant fusion proteins were expressed by transform-
ation of E. coli HB1O1 with the pGEX vectors, and induction of
protein synthesis and lysis of bacteria were performed as de-
scribed (Hashimoto et al., 1992b). Fusion proteins were isolated
by glutathione-agarose affinity chromatography, cleaved with
thrombin, and purified free of glutathione S-transferase over the
glutathione-agarose column (Guan and Dixon, 1991).
Leucocyte-common-antigen-related protein-tyrosine-phosphatases
Dephosphorylation of receptors for Insulin and epidermal growth
factor
Growth factor receptors were enriched from a solubilized mem-
brane fraction of rat liver by wheat germ agglutinin-agarose
chromatography (Kasuga et al., 1985). Receptors for insulin and
epidermal growth factor (4,ug of protein of the lectin column
eluate) were labelled in a 0.4 ml reaction mixture containing
1 ,M insulin, 5 ,ug/ml epidermal growth factor, 5 mM MnCl2,
25 ,tM ATP, 200 1tCi of (y-32P]ATP (3000 Ci/mmol) and 0.05 %
(v/v) Triton X-l00 in 50 mM Hepes, pH 7.6, at 4 °C for 60 min.
Unincorporated [32P]ATP was removed on a Bio-Gel P6 spin
column, and 25,u portions of the labelled receptors were
incubated with 1.5 ug of recombinant PTPase cytoplasmic do-
main protein in a 150,l reaction mixture containing 1 mM
dithiothreitol (DTT) and 10 mM EDTA in 50 mM Hepes,
pH 7.4, at 30 'C. After the indicated period of time, a 5 x
concentrated gel sample buffer was added and 30,1 of the
reaction volume was subjected to electrophoresis in gels con-
taining SDS and 7.5% polyacrylamide (Laemmli, 1970) and
analysed by autoradiography.
using a cDNA segment derived from the 5' end of clone 12.
Additional segments of the full-length rat LAR-PTP2 cDNA
were then compiled from additional screenings of a rat brain
cDNA library (clone RB22-2), and the remaining 882 bp of
sequence at the 5' end was obtained by using the anchored PCR
technique with rat brain mRNA (Frohman et al., 1988).
Interestingly, one cDNA clone for LAR-PTP2 from the rat brain
library screening (RB22-2) had a deleted internal segment of
1086 bp that is flanked by a sequence that exactly matches regions
of clone 12-1, suggesting that the LAR-PTP2 gene may generate
alternatively spliced mRNA products in a tissue-specific fashion
(see below).
The 6545 bp cDNA sequence of rat LAR contained a single
long open reading frame of 5697 bp. The putative translational
start site contains a well-conserved consensus sequence as defined
by Kozak (1991). The downstream methionine residue (Met-l 1)
was postulated to be the N-terminal residue of the proprotein for
human LAR (Streuli et al., 1988), but in the rat sequence this has
a less conserved consensus sequence for translation initiation.
Furthermore, nine of the first ten residues of the postulated rat
LAR precursor are identical with the human sequence, suggesting
Dephosphorylation of additional phosphoprotein substrates
MBP and RCML were phosphorylated on tyrosine residues with
partially purified recombinant insulin receptors noted above and
purified as described by Tonks et al. (199 la,b). Dephosphorylated
bovine casein (Sigma) was phosphorylated with the catalytic
subunit of cyclic AMP-dependent protein kinase (Promega),
under conditions suggested by the supplier. The 32P-labelled
casein was purified by precipitation with trichloroacetic acid and
dialysed into PTPase reaction buffer. After incubation at 30 °C
for up to 10 min, 32P released was measured by the addition of
0.90 ml of acidic charcoal mixture [0.9 M HCl, 90 mM sodium
pyrophosphate, 2 mM NaH2PO4, 4% (v/v) Norit A], sedi-
mentation of the precipitate in a Microfuge and determination of
radioactivity in 0.5 ml of the supernatant (Krueger et al., 1990).
For kinetic studies using the purified recombinant PTPases,
reactions were terminated at an appropriate time for the de-
termination of initial reaction rates.
RESULTS
cDNA cloning
Using the human LAR cDNA (Streuli et al., 1988) to probe a rat
liver cDNA library at reduced stringency, eight clones were
identified after a tertiary screening with a probe derived from a
limited region of the intracellular LAR domain (HindlIl/EcoRI
fragment). Among these initial cDNA clones, analysis of over-
lapping cDNA segments revealed that two sequences were
present. One of the cDNAs was represented by seven cDNA
clones. This sequence was nearly identical with the human LAR
cDNA sequence and represents its rat homologue (see below).
Additional segments of the full-length rat LAR cDNA were then
compiled from additional screenings of rat liver and brain cDNA
libraries. The remaining 546 bp of the 5' region was obtained by
an anchored PCR technique with rat liver mRNA (Frohman et
al., 1988).
One unique cDNA insert from the initial rat liver library
screening (clone 12 in Figure 1) had high regional homology to
the intracellular portion of the LAR cDNA but appeared to
encode a different gene product. We have termed this cDNA
LAR-PTP2. An additional segment of this relatively rare hepatic
cDNA (Figure 1, clone 9-1) was isolated by cDNA walking with
an additional one million plaques of the same rat liver library
Rat LAR-PTP2
L
0
TM
-LLiEUEEEU-
Stop
PTPase Domains
I I a I a I i
1.0 2.0 3.0 4.0 5.0 6.0 kb
Figure 1 Diagram of cONA clones encoding LAR-PTP2
The numbered inserts were isolated from a rat liver library and the insert designated RB was
from a rat brain library. The 5' sequences were obtained by anchored cDNA amplification and
labelled PCR in the diagram. The extracellular domains include three regions with homology
to immunoglobulin repeats (light stippling) and eight regions with fibronectin type IlIl homology
(dark stippling), as described in the text. The transmembrane domain (TM) and the two tandem
homologous PTPase domains in the cytoplasmic region are also shown. The dotted line in clone
RB22-2 encoding rat LAR-PTP2 indicates absent sequences that are probably due to alternative
splicing of this rat brain transcript.
rPTP2:
mN-CAM:
rLAR:
GSLLARWEPPADAAEDPVLGYRLQFGR. E
SLL+ W PP+ + GY L + E
931 TSLLLHWQPPLSHNGV. LTGYLLSYHPVE
++LL+W+PP G L GY L Y+ +
HTALLQWHPPKELPGE . LLGYRLQYRRAD
PGAETALTLQGLRPETAYELRVRAHTRRGPGP
P+ T++ L GLRP ++Y ++V+A RG GP
873 PANTTSAILSGLRPYSSYHVEVQAFNGRGLGP
+ + L GL+P ++Y ++V+A +G+GP
VTGDVHLTLLGLKPOTTYDIKVRAHTSKGAGP
rPTP2: VVVRTDEDVPSAPPRKVEAEALNATAIRVLWRSPTPGRQHGQIRGYQV
+ V T DVPSAPP+ V E +N+ +I+V W P G Q G I GY +
hDCC: 613 ITVVTLSDVPSAPPQNVSLEVVNSRSIKVSWLPPPSGTQNGFITGYKI
+ V T DVPS+PP+ V +E +NS ++ VSW P Q G I GY +
rLAR: VLVRTDEDVPSGPPRKVEVEPLNSTAVHVSWKLPVPNKQHGQIRGYQV
Figure 2 Alignment of segments of the extracellular domain of rat LAR-
PTP2 (rPTP2) and rat LAR (rLAR) with homologues in the N-CAM family,
Including mouse N-CAM (mN-CAM) and a putative human colorectal tumour
suppressor protein DCC (hDCC) (Fearon et al. 1990)
Between the amino acid sequence, identical residues are indicated with a capital letter and
conservative substitutions are shown by a (+). In a few cases, a single amino acid gap has
been introduced for alignment (.).
PTP2-PCR
........-------
RB22-2
9-1
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hLAR ......NVPL......VPALVMLGLVAGAHGDSKPVFIKVPEDQTGLSGGVASFVCQATGEPKPRITWWKKKW(VSSQRFEVIEFOQGAGSVLRIQPLRvQROEAIYECTAT
rLAR eap.papqrr--- . N~--------V---I---------------------------------
rPTPZ : ..-....A-TwrpsvvsvvgPyG-FLVL-AR-CtAEEP-R--RE-K- -l-V-------D----V--N----N----T-O- -ESS-A-----TP---NV -- -V-Q
hLAR :NSLGEINSKSLEQPGP11GQKVKRA1LAGNOESFDLVPTNRKLSAQESEOGYCANATYAALVVR
rLAR :----------D---S---T---------------------- S--------------------------
hPTPS :
.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
rPTP2 :--V---TVH---T--R-D-----N-------RT----- S-- I---T-----SA---------I--- -------V---S------
rLAR :----------N----------------------N---------------------------I---SF-
rPTP2 --L---- -I --N----S-----Q---D--P--D------ID-KO-----N----V---V--I---S---A-GTP----N----I-V----PD--S--
.-P......................--V-- -N------P-LTQ-S----A--D----ST-I----KE----QIQ------PTQHV-N-N---VADS
rPTP2 V-E-KSKSQD--Y-IKED1T-------N---EIW-S----Q---S-VT-----A-A--N-----T--I----E-V
---I-----NEPEH-VGN-Q---V-DS
hLAR :LLTTVQSLLPGITYSLRVLAFTAVGDGPPSPTIQVKTQQGVPAQPADFQAEVESDTRIQLSWLLPPQERI INELVYWA.AEDEDQQWKVTFDPTSSYTLEDLKPDTLYRFQLAARSMNGV
rLAR: --------------------------KA-----------K-------G-------------H-----
hPTP6 QI--I-N-V-QK---VK---SI----L-SD---I--TI--- G--LN-K--P--E-S-L---TP-RSDT-AN-----KDGEHGEEQRI-IE-GT--R-QG---NS--Y-R----PQ-L
rPIP2:------EDE--TVY---S---L-DP------G--N4NLR- -AK-E-S-G----SA-R--SV-K----IFREGDRGREVGR.----IAFVV---N-E-A-R----PQ-L
rIAR:----V--C
-----------T-----------I-----Y-----K-I--------L-------------------
hPTPS : -AS-AE-S---NM--K----DIS-T-PS--SILI---Q---VEKQ--I--E--IKYT----DKP-EIL--PSDTTKYL-EQ-----IT-T I-----S--I--N----
rPTP2 : -A--AVVCQ--L-AK----D-K-T-LR- -AL!.......................L-EA------TAV-Y-E------V------A
hLAR :PPRKVEVEPLNSTAVHVYWKLPVPSKQHGQIRGYQVTYVRLENGEPRGLPI IQDVNIAEAQWRPEESEDYETTISGLTPETTSVTVAAYTTKGDGARSKPKIVTTTGAVPGRPI?9IST
rLAR:----------S----N------------ Q-------------------I---------V--------V-hPTPS :-----AV---S-K-S-RS---N-------H---N4----K-Q-N4LK---D---EFDOTTEHDNI-----Q---S--L--T -I------ -S-----K-RLV-NH
rPTP2 :----A-A--A--IR-L-RS-T-GR------H---N1-GT-A--P-R-K-1---D- . ...-....NV-TN-Q---A--l--N-V-4------V-K---L----LSVQQ
hLAR :TANNIALLQWHPPKELPGE.LGRQCAERNIFKDNTTLKTYFLANALEFKITELSFQLHTLTTEADPLENR
rLAR: ---H--------------R---------------A--------P- ------ --A ------R-------------
hPTPS :
-Q---I---VDTF-P. -Q----KFG-K-N4EPLT-LE-SEKED---A-DI---AS-V---S-R-KV-F---NV---SI--EV-T--.----SE-T-STSVQ-S-Q--I----1
rPTP2 :
-PEGSL-AR-E--ADAAEDpV----FG- .ED-A-A-LELAAMERR- .AAPA---A--V----RG-----ASAAISI- --A-R---- I-gPAGNVSAGSVI-R-L- ---P--G--A-
hLAR : ISYTVVFRD.....INS....QQELQNITTOTRFTLTGLKPDTTYDIKVRAWTSKGSGPLSPSIQSRTNPVEQVFAKNFRVAAANKTSVLISWEVPDSYKSAVPFKILYNGQSV.. EV
rLAR IN----Y- . -...-----V-G-VHI--L-------- H----A-N-------1------------------------
hPTP& IK--LLY--........Ip11PN4-QLIVPA--TN4-------V----H----P--Y---V-F--L--D-----H-K-V------I-EN-N--N----DDGKN4ve--
rPTP2 :-K---SV-Eagtpgp&tETE. .. LIAAAAQPGAE-AI--Q--R-E-A-ELR---HR-RR-P--F--PLRY- .LARDP-SP---K-KNI------F--N-N-PT-Y--Q---LTL. .D-
hLAR : ONMKIOQNESVNRSAGQVITPLPPPSYEGFLMHQPLRFIVPDVGNTRSPEEDLEIQGER
rLAR :------------I---T----------Q-----F--5---
-q---Q-----------NL-A------------E-K- --hPTPB
--RATQ-.-VN-K-EKS ---T--N-t----R-TAK----V-RT--AFIGKTNL--NIIVQL-E-PAN4ENIKGY--11--LKKSR-KFIK- .-ES-D-N----KE-SRKRRSI-Y
rPTP2 :--RTTK--- -Th-K-H-F-N---- -I-I-------QT-TA-- -FNN-SG- -SV-PKPDN- -SI VVYL-DG-S-VT-QNYF--1N--LRKSR-GQFPILLGS--DMD-E-- IIDLSRLQRRSL-
hLAR : RRRQAERLKPYVAAIQLDVLPETFTLGDKKNYRGFYNRPLSPDLSYQCFVLASLKEPMVQKYASSPYSDEIVVQVTPAQ. .QQEEPELW4LVTGPVLAVILIILIVIAXIIKRKRTHSPS
rLAR :---------V-E----------------------------------------------------
hPTP6 G-. .EVE---- I--HF----TE----D-H-G--T-KQ-QSGQE-VF---- .VN-HAES-N--TI.--PV-SMDIDP-piTD--EGLI--V
----VF--C-----Y-- E
rPTP2 HS--L-VPR--I--RFSI--AV-HP-NQ-Q-G--D--G-E-GME-VL----V-QKNEPTFAASPFSDPFQLDNPDPQPI. .VDG-GL--ITT--N----R
hLAR :SKDEQSIGL .ISLASDV1RLYTGRHPPTLDIRKNGKSEEI-GFTESNEPIAVASVITIGPSDI'Y
rLAR:---------------------------------------- -S ------------
hPIPfi R-SSIPNN...EIPSH-PT----LI----F----AS----LE---H-----N-----------H-------------I-SA-E-1---V--
rPTP2 :DSEPRTKC-lnnA-LAPH-PK-----I-F-I--S-N----EHN-----S--LI---------H----A------------QPLE-IN-----
hLAR : DYKNYA&LEM?&WQTTVNREKRRQ'PAGECLQTLTEAYVTAWGSKERFF4WDGPYTIAL PTPase
rLAR:------------------I- ---------------- ----V------N- - ---- ---------------- Domain
hPTP6 ---------S----F----I----S-----K---R ------S----H--V--------C----Y-N----V-I--------H---F---- I
rPIP2 V--R-------F-------S- -N--------------Y-F-- N------1 --FC----S---N-----V-H---T--------F----
hLAR RRKCPDP1VKGVRTCIIALPWEKVIGVCSQNYVTYVIELEACHEPRLAiQ(GVPETAELFLAK
rLAR
--------------------------------------N---M---L----------------G-
hPIP6:---T-- --------------I--------L--A-------I---D---V---N------Y----T-IET--N--G----R---
v-PTP2 : --T-P--V-------------IRT---V---L---------S------VG--N----S--TY----A--E---H--G----R---
hLAR : HSFSNPWKLNWETVCLPRVGDI FDYQKYITQGLEtD*R'ENTIVNITKLRWJENRK*CHQVPAERSARYQYFVVDPN4A
hPTP6 ------------- S------------I----------T---------V------------------
v-PTP2 L---SS -----------I-I--------- ---A---N----V------------------
hLAR EYMQIRFVORGSTRFFDEG*KGGIFGVTEFQIIVWVTVILILRREVDQVT*TAAIE*YL PTPase
rLAR------------------------------------------------------------ - - --Domain
hPTPE ------------ V-------- S------------- S----------------I----N ---------F I
rPTP V-------A--S------------A--S ---------------- ---V--------E--F
hIMR CYRAALEYLGSFDHYAT
rIAR --- --- ----
hPTPS
--
-- ----
rPTP2 -FQ ----- -----
Figure 3 Alignment of amino acid sequences deduced from the cDNAs for human LAR (hIAR), rat LAR (rIAR), human PTP-4 (hPTP6) and rat LAR-PTP2
(rPTP2) as determined by the algorithms In the EuGene DNA anaiysis programs
As shown, human PTP-4 contains the available partial sequence data (Krueger et al., 1990). The sequence comparison is presented as tollows: upper case, aligned non-identical residues; lower
case, unaligned residues;--, aligned identical residues;.., a gap introduced tor optimal alignment. The transmembrane domains are highlighted by underlining. The regions containing the
tandem intracellular PTPase domains are indicated, along with residues that are conserved in the PTPase catalytic domains which are highlighted by an asterisk over the human LAR sequence
(Krueger et al., 1990).
that the actual translation start site for the human LAR cDNA cellular domain of 1224 residues, 24 hydrophobic residues
may be the more proximal methionine residue. Using the comprising a single transmembrane segment (Met-1252-Phe-
algorithm of von Heijne (1986), the signal peptide cleavage site 1275) and a cytoplasmic domain of 623 amino acids. This
is predicted to occur between Ala-27 and His-28. Thus the sequence is identical with the partial rat LAR cDNA sequence
mature protein contains 1871 amino acids, including an extra- (854 amino acids) reported by Pot et al. (1991) with the exception
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of five positions where Thr-1073, Ile-1434, Gly-1639, Arg-1643
and Ala- 1644 in our sequence are replaced by Ser, Thr, Asn, His
and Thr respectively in the sequence of Pot et al. (1991).
The cDNA sequence of rat LAR-PTP2 consisted of 6469 bp,
with a single long open reading frame of 5592 bp. There is a
single in-frame termination codon upstream (ntl 16) of the
putative translational start site (ntl85) which contains a well-
conserved initiation sequence; the signal-peptide-cleavage site is
predicted to occur between Gly-26 and Cys-27. Thus the mature
protein contains 1837 residues, which includes an extracellular
domain of 1186 residues, 25 hydrophobic residues in the single
transmembrane domain (Gly-1213-Tyr-1237) and a cytoplasmic
domain of 626 amino acids. The alternative sequence of the
LAR-PTP2 cDNA found in clone RB22-2 from rat brain shortens
the extracellular domain by 362 amino acids (Figure 1). We have
termed the protein resulting from the translation of this
alternatively spliced mRNA LAR-PTP2B.
Homology comparisons with the deduced amino acid
sequences of rat LAR and LAR-PTP2 were performed against
the translated version of the GenBank database (Figure 2).
Similarly to data reported for other receptor-type PTPases
(Streuli et al., 1988), the extracellular domain of both LAR and
LAR-PTP2 had striking regional homologies to certain
fibronectin domains (Kornblihtt et al., 1985) and portions of the
neural cell adhesion molecule (N-CAM) structure (Cunningham
et al., 1987). In addition, both rat LAR and LAR-PTP2 have
marked segmental homology to a putative colorectal tumour
suppressor protein that has structural similarities to the N-CAM
family (Fearon et al., 1990), but whose function is unknown.
LAR and LAR-PTP2 proteins have a high degree of amino
acid identity in each of the defined functional domains (Figure
3). The rat LAR homologue had 95.3% overall sequence identity
to human LAR with even higher identities in the transmembrane
(100 %) and cytoplasmic (98.2 %) PTPase domains. PTP-2 had
an overall structural organization that was similar to that of
human LAR. These features included three immunoglobulin-
type cysteine repeats near the N-terminus with high conservation
of the consensus D-X-A(G)-X-Y-X-C sequence around the second
cysteine residue of each repeat in both LAR and LAR-PTP2
(Cunningham et al., 1987). Both proteins also exhibited eight
fibronectin type-III repeats in the extracellular domain. The
alternatively spliced segment of the rat brain cDNA encoding
LAR-PTP2B effectively removes the fourth-sixth fibronectin
type III repeats. Despite their overall conservation of sequence
identity, the rat LAR and LAR-PTP2 sequences diverge
significantly in many areas of the extracellular domain, especially
near the transmembrane segment and in the proximal portion of
the cytoplasmic domain near the membrane. Interestingly, in the
internal portion, the amino acid identity between rat LAR-PTP2
and rat LAR is greater in the second PTPase region (89.6 %)
than in the proximal domain (78.7 %), as has been noted for
other tandem-domain PTPases (Krueger et al., 1990). In com-
parison with the published partial sequence for human PTP-8, a
human transmembrane PTPase phylogenetically related to LAR
(Krueger et al., 1990), LAR-PTP2 has 59.3 % overall identity.
Interestingly, the extracellular domain of rat LAR-PTP2 was
more closely related to LAR than to human PTP-8 (56.70%
identity compared with 40.2 %). These data indicate that there is
a family of LAR-related receptor-like PTPases that may have
arisen by gene duplication. Differences in the overall sequence
similarity between LAR-PTP2 and human PTP-8, however,
suggest that it is not simply the rat homologue of human PTP-
8. The substantial sequence variation in the extacellular domain
also implies that it may have a functional role in the rat that is
different from PTP-8 in human tissues.
cDNA probes:
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Figure 4 Southern-blot analysis of rat genomic DNA digested with either
Hindill (H) or EcoRI (E) and hybridized with cDNA probes from human LAR
(hLAR), rat LAR (rLAR) or rLAR-PTP2 as indicated
The sequence origin of the cDNA probes is shown schematically in the lower panel; the hLAR
probe was an EcoRl/Hindlll fragment, the rLAR probe was an EcoRl fragment of clone 18-2,
and the rLAR-PTP2 probe was an Apal fragment of clone 12. Note that the EcoRl site is
converted between the human and rat LAR cDNAs but is not present at that position in the rLAR-
PTP2 cDNA sequence.
Blot hybridization studies
Southern-blot analysis with rat genomic DNA indicated that the
human LAR domain probe (HindIll/EcoRI fragment) hybridizes
only with two discrete fragments of HindIII-digested rat DNA
under the reduced stringency conditions used in the library
screening (Figure 4). Interestingly, the 20 kb genomic fragment
hybridizes only with a cDNA segment from the PTPase domain
of the rat LAR clone, whereas the 9.0 kb fragment hybridizes
predominantly with the cDNA probe derived from an identical
region of the conserved first PTPase domain of LAR-PTP2.
These data suggest that the probe used in the initial library
screening cross-reacts with genomic segments derived from the
coding regions of the two closely related PTPase genes that have
been isolated. With EcoRI-digested genomic DNA, the human
LAR cDNA probe hybridizes to different genomic fragments
from the rat LAR cDNA probe because the converted EcoRI site
in the cDNA prevents cross-hybridization between the restricted
genomic exons and the probe cDNA sequences. The human
LAR and LAR-PTP2 probes each hybridize with a large 24 kb
fragment of EcoRI-digested rat genomic DNA, however, since
there is potential sequence overlap between these homologous
probe sequences. Furthermore, hybridization of EcoRI-digested
rat genomic DNA with cDNA segments of rat LAR and LAR-
PTP2 taken from identical regions of the first PTPase domain
revealed distinct simple patterns, providing further evidence that
each of these cDNA sequences corresponds to unique single-
copy genes.
The expression of rat LAR and LAR-PTP2 was evaluated by
Northern-blot analysis using poly(A)+ RNA from several rat
tissues. In preliminary studies using the probes from the cyto-
plasmic domain indicated in Figure 4, rat LAR cDNA hybridized
to a major mRNA transcript of 8.0 and a minor band of 5.3 kb
in liver. The 8.0 kb mRNA was also expressed in kidney and to
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seen in kidney, heart, lung, spleen, testis and skeletal muscle,
with no apparent expression of the smaller mRNA species.
Interestingly, brain RNA contained a transcript that co-migrated
with the 4.6 kb liver mRNA for LAR and a diffuse signal
suggesting additional size mRNAs. The diffuse signal might also
suggest cross-reactivity with other related PTPases in brain, but
this is less likely given the high stringency of the hybridization
and the lack of cross-reactivity on these blots between LAR and
its close homologue LAR-PTP2 (see below). The hybridization
signal of the same blot with a probe for f6-actin attests to the
integrity of the RNA preparation.
In contrast, Northern-blot analysis of the same blot using a
cDNA probe encompassing the entire cytoplasmic domain of
LAR-PTP2 revealed a single mRNA transcript of 7.3 kb with
predominant expression in heart, testis and liver, and lesser
expression in skeletal muscle, spleen, brain and kidney (Figure
5). By examining the superimposed blots for LAR and LAR-
PTP2, the high-molecular-size transcript for LAR is measurably
larger than the LAR-PTP2 mRNA. In the blot shown in Figure
5 and in independent Northern-blot hybridizations (not shown),
a major transcript for LAR-PTP2 was also observed at 6.0 kb
which was expressed to a high level only in brain tissue.
Additional mRNA species for LAR-PTP2 are apparent in the
range of - 2.6 to 4.4 kb. Reverse transcription and cDNA
amplification of brain RNA with primers flanking the
alternatively spliced domain of LAR-PTP2 revealed products of
- 1.9 kb as well as smaller products in the 200-400 bp range,
providing further evidence that both forms of the LAR-PTP2
mRNA are expressed in brain tissue (results not shown). The
presence of multiple splice forms of the LAR-PTP2 transcripts
may also account for the broad multiple bands we and others
have observed on Northern-blot analysis of PTP-2 in brain (Yan
et al., 1993; Pan et al., 1993).
(c)
Figure 5 Northern-blot analysis of mRNA from several rat Ussues using
rat LAR (a), LAR-PTP2 (b) and h8-actln (c) cDNAs as probes
Electrophoresis in 1 % agarose gels containing 3 % (v/v) formaldehyde was performed with 2 #sg
of poly(A)+ RNA from rat heart (H), brain (B), spleen (S), lung (L), liver (Li), skeletal muscle
(M), kidney (K) and testis (T). The RNAs were transferred to nylon filters and hybridized at high
stringency according to the manufacturer's instructions (Clontech). For these blots, the cDNA
probes were the entire cytoplasmic domains of LAR and LAR-PTP2 and a 2 kb human f8-actin
control probe used sequentially on the same blot. The positions of RNA size markers are also
indicated.
a lesser extent in brain and spleen. These results are essentially in
agreement with Northern-blot data from human cell lines (Streuli
et al., 1988). Using the entire rat LAR cytoplasmic domain as a
probe, hybridization ofmRNA from multiple rat tissues showed
predominant expression of LAR in liver as an 8.0 kb mRNA,
with two minor bands at - 5.0 and - 4.6 kb (Figure 5). In
decreasing order, expression of the 8.0 kb transcript was also
Catalytic activity of LAR and LAR-PTP2 cytoplasmic domains
In order to examine the enzyme activity of the catalytic domains
of the cloned PTPases, the entire cytoplasmic domains of LAR
and LAR-PTP2 were expressed as recombinant glutathione S-
transferase fusion proteins using the pGEX-KG vector. The
PTPase domains were cleaved from the fusion product and
purified essentially to homogeneity. Both protein domains
migrated at the expected molecular size of approx. 72 kDa
(results not shown).
The catalytic activity of the recombinant PTPase domains was
tested in vitro towards the simultaneous dephosphorylation of
intact autophosphorylated receptors for insulin and epidermal
growth factor prepared from rat liver membranes (Figure 6). In
these studies, the dephosphorylation of the 95 kDa insulin
receptor f-subunit and the 170 kDa epidermal growth factor
receptor protein was assessed by gel electrophoresis and auto-
radiography of the receptor polypeptides after incubation with
the purified PTPase enzymes. In the control receptor preparation,
minimal dephosphorylation of the intact receptors was observed
during the incubation period. After incubation with recombinant
LAR or LAR-PTP2, both autophosphorylated receptors were
simultaneously dephosphorylated with no significant difference
in the relative PTPase activity towards the dephosphorylation of
either insulin or epidermal growth factor receptors.
The purified LAR and LAR-PTP2 cytoplasmic domains were
also used to study catalytic properties of their encoded PTPases.
Casein, phosphorylated with the catalytic subunit of cyclic AMP-
dependent protein kinase, was not dephosphorylated by either
LAR or LAR-PTP2 over background (not shown). As a control,
calf intestinal alkaline phosphatase (Promega) rapidly de-
(a)
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Control LAR LAR-PTP2
Time (min) 0 15 30 60 90 0 15 30 60 90 0 15 30 60 90
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Figure 6 Simultaneous dephosphorylation of intact autophosphorylated
receptors for insulin and epidermal growth factor by the catalytic domains
of rat LAR and LAR-PTP2
Purified recombinant cytoplasmic domains of LAR and LAR-PTP2 were used to dephosphorylate
insulin and epidermal growth factor receptors as described in the Experimental section. After
the indicated period of time, a stop solution was added and the receptors were analysed by gel
electrophoresis and autoradiography. The positions of the 95 kDa insulin receptor fl-subunit
(INS-R) and the 170 kDa epidermal growth factor receptor (EGF-R) are shown.
Table 1 Effect of various compounds on the catalytic activlty of purflEed
LAR and LAR-PTP2
The data shown represent the percentage of control dephosphorylation of MBP or RCML in the
absence of effector; the mean value of at least two experiments is given. nd, Not determined.
LAR
activity (%)
Addition Concentration MBP RCML
None
Na3VO4
Ammonium
molybdate
Spermine
EDTA
1 00 INM
1 mM
10 ,uM
100 ,uM
2 mM
5 mM
100
2.7
2.5
48
19
159
123
100
51
21
70
0
75
62
Table 2 KinetIc parameters of purifed LAR and LAR-P
domains
The specific activity is expressed as nmol of Pi released/min per mg of pr
linear reaction rate using 0.2 #sg of each PTPase for the reaction with ME
for RCML. Vmu. is expressed as nmol of Pi released/min and
Michaelis-Menten kinetics. The turnover number is nmol of Pi releas
enzyme.
LAR LAR-P
Parameter MBP RCML MBP
Specific activity
Km (1sM)
VMITma u
Turnover number
706
4.35
1.18
424
5550
7.93
2.50
8990
350
2.92
0.6
233
phosphorylated more than 50% of the labelled ca
In contrast, tyrosine-phosphorylated MBP and
actively dephosphorylated by both PTPases (se(
cating their catalytic specificity for protein phosphotyrosine
residues.
A series of effectors that have previously been shown to
stimulate or inhibit various PTPases was tested with the LAR
and LAR-PTP2 enzymes using both MBP and RCML as
substrates (Table 1). Sodium vanadate was inhibitory to both
enzymes, although the Y. (IC50) was substantially higher for
LAR using RCML as substrate (100 ,uM) than for MBP with
either enzyme or for RCML with LAR-PTP2. Another PTPase
inhibitor, ammonium molybdate, was inhibitory to both enzymes
but LAR appeared less sensitive than LAR-PTP2 with both
substrates. Interestingly, spermine and EDTA demonstrated
similar effects on both PTPase enzymes; these compounds were
moderately inhibitory to RCML dephosphorylation but
stimulatory to dephosphorylation of MBP.
Kinetic parameters were also determined for LAR and LAR-
PTP2 using both substrates (Table 2). There was a close range of
Km values for these artificial substrates varying between 3 and
8 ,uM. The turnover numbers calculated for MBP were 4 and
7 s-I for LAR-PTP2 and LAR respectively assuming a single
catalytic centre for each cytoplasmic domain. For RCML, these
values were substantially higher (78 and 150 s-' for LAR-PTP2
and LAR respectively), indicating a marked catalytic preference
of these enzymes for RCML as a substrate compared with MBP.
DISCUSSION
LAR-TrP The present study was performed initially to characterize PTPases
activity (%) that occur in liver and have a potential role in the regulation of
MBP RCML the phosphorylation state of growth factor receptors in this
tissue. Our strategy follows data from several laboratories which
100 100 have demonstrated that as much as 75-85 % of the total insulin
0 10 receptor PTPase activity is found in the particulate fraction of
0 0 liver and that the highest specific enzyme activity is present in a
1.5 12 glycoprotein fraction of solubilized liver membranes, suggesting
nd nd that the PTPase that acts to dephosphorylate the insulin receptor
124 78 in liver might itself be a plasma-membrane glycoprotein131 58 (Goldstein et al., 1991). Other work has supported this hy-
pothesis, including studies with permeabilized adipocytes
(Mooney and Anderson, 1989) and insulin receptor de-
phosphorylation in liver endosomes (Faure et al., 1992).
'TP2 cytoplasmic As the transmembrane PTPase LAR, or a closely relatedhomologue, is predominantly expressed in liver tissue in the rat
otein and is the initial (Goldstein et al., 1991), we used the human LAR cDNA as a
BP and 0.02 At, each probe to screen for homologous PTPases in a rat liver cDNA
was determined by library. Using this strategy, we have identified the full-length
sed/min per nmol of sequence for the rat homologue of LAR as well as a closely
related unique member of the LAR PTPase family, called LAR-
PTP2, which is transcribed from a unique rat gene. The relative
TP2 abundance of the isolated cDNA clones suggests that the mRNAs
from which they are derived are quite rare. On the basis of the
RCML number of independent clones isolated from multiple screenings
of the original cDNA library, rat LAR mRNA apparently
3720 represents seven copies per million, similar in magnitude to the
4 3.34 abundance of rat insulin receptor mRNA which we have cloned
43 1.33 from the same library (Goldstein and Dudley, 1990). The LAR-4780 PTP2 cDNA is quite rare in liver, and is present on average at
only one copy per million.
Comparison of the amino acid sequences among the PTPases
isolated in this report provides further evidence for a family of
transmembrane PTPases in human and rodent tissues that are
closely related to LAR, including LAR-PTP2 and PTP-l
isein substrate. (Krueger et al., 1990; Mizuno et al., 1993). As described above,
RCML were it is of interest that Southern-blot analysis using the conserved
e below), indi- PTPase domain cDNA probe for human LAR and HindlIl-
An nTrn
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restricted rat genomic DNA identified only two genomic segments
that appear to be derived from the genes for rat LAR and LAR-
PTP2 respectively (Figure 4). Since a third fragment corre-
sponding to a potential rat gene for PTP-8 was not observed,
these findings suggest that perhaps LAR-PTP2 and PTP-8 arose
as a result of divergent molecular evolution from an ancestral
LAR-related PTPase homologue that arose initially by gene
duplication.
The extracellular domains of rat LAR and LAR-PTP2 share
several common structural features with the human PTPases,
LAR, PTP-,/ and PTP-8, and the Drosophila homologues, DPTP
and DLAR (Streuli et al., 1989). These include regional
homologies to fibronectin type III domains and the related N-
CAM structure (Figure 2). These structural determinants suggest
that these transmembrane 'receptor-like' PTPases may be
regulated by the homotypic interactions that are characteristic of
cell adhesion molecules. Unique regions in the extracellular
domains of these enzymes may interact with other cell-surface
molecules or specific circulating ligands which may exert a
regulatory influence on the activity of the cytoplasmic PTPase
domains, as has been demonstrated in studies with recombinant
epidermal growth factor receptor-CD45 chimaera (Desai et al.,
1993).
The expression of an alternatively spliced form of LAR-PTP2
(LAR-PTP2B) may also have tissue-specific functional effects, as
this protein apparently lacks three of the eight fibronectin type
III domains found in the extracellular domain of the full-length
LAR-PTP2 expressed in liver. This sequence variation may have
functional significance for the expression of LAR-PTP2 in
various brain cell types or in its regional distribution. Alternative
splicing of receptor-type PTPase mRNAs has been noted to
affect both the extracellular and cytoplasmic domains (Streuli et
al., 1987; Matthews et al., 1990; Barnea et al., 1993; Mizuno et
al., 1993). During preparation of this paper, a report appeared
documenting an additional splice variant of LAR-PTP2B that
differentially uses polyadenylation sites leading to a truncated
cytoplasmic segment lacking the second PTPase domain (Pan et
al., 1993). Also, mapping of LAR-PTP2B in mRNA in brain by
in sirn hybridization has demonstrated high levels of expression
in neurons localized to the olfactory neuroepithelium (Walton et
al., 1993).
Streuli et al. (1992) and Yu et al. (1992) have shown that the
extracellular domain of LAR is post-translationally processed by
proteolytic cleavage and is non-covalently associated with the
transmembrane segment in transfected cells. Further studies by
these authors also demonstrated that a conserved penta-arginine
sequence at the distal end of the extracellular domain of LAR is
likely to function as a proteolytic processing site. This site is fully
conserved in the rat and human LAR sequences, and a similar
sequence (RKRR) appears in the same region of human PTP-8.
A similar polybasic motif is absent from the LAR-PTP2 protein,
suggesting that LAR-PTP2 may have a different biosynthetic
itinerary than LAR, and exist as an intact transmembrane
PTPase with a large extracellular domain. Alternatively, LAR-
PTP2 may be recognized by an enzyme with a unique specificity
than can proteolytically process the extracellular domain in a
fashion similar to LAR.
Expression of the recombinant cytoplasmic domains of rat
LAR-PTP2 and LAR in a bacterial system revealed that they
encode active PTPase enzymes. In in vitro studies, the catalytic
domains of rat LAR and LAR-PTP2 demonstrated a lack of
specificity for the two holoreceptor substrates, whose auto-
phosphorylated tyrosine residues occur in completely different
sequence contexts. These results are similar to the dephosphoryl-
series of transmembrane PTPases including LAR, PTP-a, PTP-
,B and PTP-6 as reported by Krueger et al. (1990), where the ratio
of activity between the peptide and protein substrates among
these PTPases varied only between 0.28 and 0.33. However, there
may be site-specific differences in the dephosphorylation of
individual sites by LAR and LAR-PTP2 in the multiply
phosphorylated protein substrates, as we have also demonstrated
in vitro for the cytoplasmic domain of rat LAR compared with
rat LRP (PTP-a) and PTPaselB (Hashimoto et al., 1992a).
Kinetic parameters calculated for homogeneously purified
LAR and LAR-PTP2 showed they have high turnover numbers
for both MBP and RCML (Table 2). LAR had a higher specific
activity with linear reaction rates than LAR-PTP2, although the
Km values were also slightly higher for LAR. The calculated
turnover numbers for LAR of 7 s-' for MBP and 150 s-I for
RCML are similar to those reported for the rat LAR cytoplasmic
domain of 3-6 s-' using p-nitrophenyl phosphate or phosphoryl-
ated angiotensin I respectively (Pot et al., 1991) and 20-70 s-5 in
experiments using a variety of non-radioactive phosphotyrosyl
peptides (Cho et al., 1991, 1992).
As the intracellular domains of several of the transmembrane
PTPases appear to have functional similarities, it is likely that
their potential in vivo substrate specificity and their physiological
roles are determined by the specificity of their tissue expression,
as well as the structure of the extracellular domains in the intact
proteins which may affect their interaction with cell surface
proteins or regulatory ligands. Rat LAR and PTP-2 have
strikingly divergent sequences in the region immediately sur-
rounding the transmembrane domain and in the extracellular
domain which may influence the function of these proteins in
intact cells. Furthermore, subtle variations in the catalytic
sequence of these PTPases, or the possible influence of specific
cellular protein PTPase inhibitors (Ingrebritsen, 1989), may also
direct their specificity or activity towards their actual physio-
logical substrates in vivo. Further studies involving eukaryotic
expression of various membrane-linked and soluble forms of
the cloned PTPases in appropriate host cells will allow these
hypotheses to be tested more directly.
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